Impax Laboratories Inc. et al v. Lannett Holdings Inc. et al
||Impax Laboratories Inc. and AstraZeneca AB
||Lannett Holdings Inc. and Lannett Company Inc.
||July 25, 2014
||US District Court for the District of Delaware
||Leonard P. Stark
|Nature of Suit:
|Cause of Action:
|Jury Demanded By:
Access additional case information on PACER
Available Case Documents
The following documents for this case are available for you to view or download:
|March 29, 2017
TRIAL OPINION. Defendants have failed to prove the Dearn patents are invalid. If desired, Defendants should request an opportunity to cross-examine Ms. Allen within one week. If Defendants do not make that request, the parties should submit an agreed upon form of final judgment within two weeks. Signed by Judge Richard G. Andrews on 3/29/2017. (nms)
|December 1, 2015
MEMORANDUM OPINION providing claim construction for disputed terms in U.S. Patent Nos. 6,750,237 and 7,220,767. Within five days the parties shall submit a proposed order consistent with this Memorandum Opinion. Signed by Judge Richard G. Andrews on 12/1/2015. (nms)
|December 10, 2014
MEMORANDUM ORDER Consolidating Cases and Denying Motion to Dismiss (see D.I. 9 in 14cv984-RGA). Signed by Judge Richard G. Andrews on 12/10/2014. Associated Cases: 1:14-cv-00984-RGA, 1:14-cv-00999-RGA(nms)
Use the links below to access additional information about this case on the US Court's PACER system.
A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
Why Is My Information Online?